​

Lantheus (LNTH) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Lantheus Revenue Highlights

Latest Revenue (Y)

$1.53B

Latest Revenue (Q)

$378.73M

Main Segment (Y)

Product

Main Geography (Y)

US Segment

Lantheus Revenue by Period

Lantheus Revenue by Year

DateRevenueChange
2024-12-31$1.53B18.32%
2023-12-31$1.30B38.65%
2022-12-31$935.06M119.91%
2021-12-31$425.21M25.28%
2020-12-31$339.41M-2.28%
2019-12-31$347.34M1.15%
2018-12-31$343.37M3.62%
2017-12-31$331.38M9.78%
2016-12-31$301.85M2.86%
2015-12-31$293.46M-2.70%
2014-12-31$301.60M6.32%
2013-12-31$283.67M-1.54%
2012-12-31$288.11M-19.14%
2011-12-31$356.29M-

Lantheus generated $1.53B in revenue during NA 2024, up 18.32% compared to the previous quarter, and up 441.62% compared to the same period a year ago.

Lantheus Revenue by Quarter

DateRevenueChange
2024-09-30$378.73M-3.90%
2024-06-30$394.09M6.52%
2024-03-31$369.98M4.51%
2023-12-31$354.00M10.64%
2023-09-30$319.95M-0.55%
2023-06-30$321.70M6.95%
2023-03-31$300.78M14.29%
2022-12-31$263.17M9.98%
2022-09-30$239.29M6.96%
2022-06-30$223.72M7.11%
2022-03-31$208.88M61.22%
2021-12-31$129.56M26.93%
2021-09-30$102.07M1.00%
2021-06-30$101.06M9.25%
2021-03-31$92.51M-1.75%
2020-12-31$94.15M6.33%
2020-09-30$88.54M34.14%
2020-06-30$66.01M-27.22%
2020-03-31$90.70M1.52%
2019-12-31$89.35M4.16%
2019-09-30$85.78M0.08%
2019-06-30$85.70M-0.93%
2019-03-31$86.51M0.28%
2018-12-31$86.27M-2.96%
2018-09-30$88.90M3.89%
2018-06-30$85.57M3.56%
2018-03-31$82.63M1.71%
2017-12-31$81.24M1.63%
2017-09-30$79.94M-10.01%
2017-06-30$88.84M9.19%
2017-03-31$81.36M9.43%
2016-12-31$74.35M1.76%
2016-09-30$73.06M-6.29%
2016-06-30$77.97M1.95%
2016-03-31$76.47M7.41%
2015-12-31$71.20M-3.94%
2015-09-30$74.12M1.10%
2015-06-30$73.31M-2.02%
2015-03-31$74.82M-2.79%
2014-12-31$76.97M1.70%
2014-09-30$75.68M0.09%
2014-06-30$75.61M3.10%
2014-03-31$73.34M2.33%
2013-12-31$71.67M1.82%
2013-09-30$70.39M-0.31%
2013-06-30$70.60M-0.59%
2013-03-31$71.02M-

Lantheus generated $378.73M in revenue during Q3 2024, up -3.90% compared to the previous quarter, and up 117.73% compared to the same period a year ago.

Lantheus Revenue Breakdown

Lantheus Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
License and Royalty Revenues$9.13M$33.36M$48.02M$24.85M-
Techne Lite$95.49M$87.37M$88.86M$91.29M-
Strategic Partnerships And Other$38.18M$51.88M$46.87M$25.30M-
DEFINITY$317.79M$279.77M$244.99M$232.76M-
Radiopharmaceutical Oncology$1.06B$854.43M$531.51M$48.89M-
Product$1.52B$1.26B---
PYLARIFY$1.06B$851.30M$527.40M$43.41M-
Other Radiopharmaceutical Oncology$384.00K$3.13M$4.10M$5.47M-
Other Precision Diagnostics$24.23M$22.98M$22.82M$26.97M-
Total Precision Diagnostics$437.51M$390.12M$356.68M$351.02M-
Product Revenue, Net--$887.04M$400.36M-
International Segment----$44.61M
US Segment----$294.80M

Lantheus's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (33.41%), Radiopharmaceutical Oncology (23.19%), PYLARIFY (23.18%), Total Precision Diagnostics (9.59%), DEFINITY (6.96%), Techne Lite (2.09%), Strategic Partnerships And Other (0.84%), Other Precision Diagnostics (0.53%), License and Royalty Revenues (0.20%), and Other Radiopharmaceutical Oncology (0.01%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Mar 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
DEFINITY$86.16M$76.97M$78.10M$76.56M$67.34M$70.53M$68.82M$63.62M$60.74M$62.31M$58.33M$59.31M$57.64M$59.84M$55.97M-----
Total Precision Diagnostics$117.46M$103.73M$112.11M$104.21M$96.35M$97.58M$95.62M$94.37M$89.01M$87.11M$86.20M$87.04M$87.88M$90.36M$85.75M-----
Techne Lite$25.11M$20.48M$28.19M$21.71M$23.27M$21.59M$20.99M$24.73M$22.09M$19.44M$22.61M$22.04M$22.68M$23.77M$22.80M-----
Strategic Partnerships And Other$7.70M$15.25M$8.72M$6.51M$7.32M$12.78M$8.98M$7.24M$5.60M$5.45M$28.58M$6.84M$5.30M$7.90M$5.25M-----
Radiopharmaceutical Oncology$265.95M$259.76M$273.25M$259.25M$216.28M$211.34M$196.19M$161.56M$144.68M$131.16M$94.10M$35.68M$8.89M$2.81M$1.50M-----
Product$388.11M$374.60M$392.76M$369.31M$319.51M$314.08M$292.26M$233.37M$217.78M$180.01M$96.68M$93.56M$87.32M-------
PYLARIFY$265.95M$259.76M$273.25M$258.87M$215.43M$210.52M$195.47M$160.64M$143.75M$130.23M$92.78M---------
Other Radiopharmaceutical Oncology--$384.00K$848.00K$818.00K$717.00K$919.00K$928.00K$928.00K$1.33M----------
Other Precision Diagnostics$6.19M$6.28M$5.83M$5.93M$5.74M$5.45M$5.81M$6.02M$6.17M$5.36M$5.26M$5.68M$7.56M$6.74M$6.98M-----
License and Royalty Revenues$3.00M$4.13M$1.33M$662.00K$438.00K$7.62M$8.53M$7.29M$5.93M$5.94M$28.87M$6.76M$5.39M$7.50M$5.19M-----
International Segment---------------$12.97M$11.07M$8.61M$11.96M$10.63M
US Segment---------------$81.18M$77.47M$57.40M$78.75M$78.72M

Lantheus's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (33.30%), Radiopharmaceutical Oncology (22.82%), PYLARIFY (22.82%), Total Precision Diagnostics (10.08%), DEFINITY (7.39%), Techne Lite (2.15%), Strategic Partnerships And Other (0.66%), Other Precision Diagnostics (0.53%), and License and Royalty Revenues (0.26%).

Lantheus Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 19Dec 18
US Segment$294.80M$72.53M-
Worldwide-$347.34M-
UNITED STATES--$288.58M
All Other--$54.79M

Lantheus's latest annual revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Quarterly Revenue by Country

CountryDec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
US Segment$81.18M$77.47M$57.40M$19.36M$78.72M$74.65M$75.19M$75.43M$72.75M$70.25M$74.09M$71.49M

Lantheus's latest quarterly revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Lantheus Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
NBIXNeurocrine Biosciences$2.36B$622.10M
ALKSAlkermes$1.56B$378.14M
LNTHLantheus$1.53B$378.73M
AMPHAmphastar Pharmaceuticals$712.81M$188.82M
PCRXPacira BioSciences$700.97M$168.57M
COLLCollegium Pharmaceutical$631.45M$159.30M
ANIPANI Pharmaceuticals$614.38M$148.33M
IRWDIronwood Pharmaceuticals$351.41M$91.59M
DVAXDynavax$277.25M$79.34M
AVDLAvadel Pharmaceuticals$169.12M$50.02M
AQSTAquestive Therapeutics$57.56M$13.54M
DERMJourney Medical$56.13M$14.86M

LNTH Revenue FAQ

What is Lantheus’s yearly revenue?

Lantheus's yearly revenue for 2024 was $1.53B, representing an increase of 18.32% compared to 2023. The company's yearly revenue for 2023 was $1.3B, representing an increase of 38.65% compared to 2022. LNTH's yearly revenue for 2022 was $935.06M, representing an increase of 119.91% compared to 2021.

What is Lantheus’s quarterly revenue?

Lantheus's quarterly revenue for Q3 2024 was $378.73M, a -3.90% decrease from the previous quarter (Q2 2024), and a 18.37% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $394.09M, a 6.52% increase from the previous quarter (Q1 2024), and a 22.50% increase year-over-year (Q2 2023). LNTH's quarterly revenue for Q1 2024 was $369.98M, a 4.51% increase from the previous quarter (Q4 2023), and a 23.00% increase year-over-year (Q1 2023).

What is Lantheus’s revenue growth rate?

Lantheus's revenue growth rate for the last 3 years (2022-2024) was 64.04%, and for the last 5 years (2020-2024) was 351.93%.

What are Lantheus’s revenue streams?

Lantheus's revenue streams in c 24 are License and Royalty Revenues, Techne Lite, Strategic Partnerships And Other, DEFINITY, Radiopharmaceutical Oncology, Product, PYLARIFY, Other Radiopharmaceutical Oncology, Other Precision Diagnostics, and Total Precision Diagnostics. License and Royalty Revenues generated $9.13M in revenue, accounting 0.20% of the company's total revenue, down -72.64% year-over-year. Techne Lite generated $95.49M in revenue, accounting 2.09% of the company's total revenue, up 9.29% year-over-year. Strategic Partnerships And Other generated $38.18M in revenue, accounting 0.84% of the company's total revenue, down -26.40% year-over-year. DEFINITY generated $317.79M in revenue, accounting 6.96% of the company's total revenue, up 13.59% year-over-year. Radiopharmaceutical Oncology generated $1.06B in revenue, accounting 23.19% of the company's total revenue, up 23.85% year-over-year. Product generated $1.52B in revenue, accounting 33.41% of the company's total revenue, up 20.72% year-over-year. PYLARIFY generated $1.06B in revenue, accounting 23.18% of the company's total revenue, up 24.26% year-over-year. Other Radiopharmaceutical Oncology generated $384K in revenue, accounting 0.01% of the company's total revenue, down -87.73% year-over-year. Other Precision Diagnostics generated $24.23M in revenue, accounting 0.53% of the company's total revenue, up 5.44% year-over-year. Total Precision Diagnostics generated $437.51M in revenue, accounting 9.59% of the company's total revenue, up 12.15% year-over-year.

What is Lantheus’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Lantheus was Product. This segment made a revenue of $1.52B, representing 33.41% of the company's total revenue.